All posts by imreal

PPE Supply Canada Supports Breast Cancer Awareness Month Through Mask Purchases


News Image

PPE Supply Canada’s mission has always been focused on helping their communities stay protected, in addition to finding ways to give back however they can. This initiative has not only provided PPE Supply Canada with the opportunity to contribute to an important cause but has also created the opportunity for thousands of others.

“At this point in time we see wearing a mask as an act of kindness, and we’re always looking for ways the company can extend that kindness even further,” says Hussein Dhalla, founder and owner of PPE Supply Canada. “Now our customers can feel even better about their purchase, knowing that, not only are they protecting themselves and those around them, but a portion of the sale is going to the Canadian Cancer Society in support of the breast cancer community as well,” he adds.

This donation applies to PPE Supply Canada’s special KN95 mask variant, which is available in two shades of pink, in addition to their pink ASTM level 3 masks. A total of $5.00 is donated from each box/pack purchased, meaning if five (5) boxes/packs are purchased, $25.00 in total is donated.

PPE Supply Canada’s house brand of pink KN95 and ASTM disposable face masks can be found via their online store, http://www.ppe-supply.com and are currently available for purchase for all.

If you’re an organization or business interested in a bulk order of pink KN95 or ASTM disposable face masks in support of Breast Cancer Awareness Month, please reach out to PPE Supply Canada directly at 647-577-2624.

About PPE Supply Canada:

PPE Supply Canada is a Toronto-based personal protective equipment retailer. Focusing on the needs of its communities, the company strives to provide exceptional experiences alongside high-quality personal protective equipment that has been trusted by its diverse customer base throughout the pandemic. All of their orders are shipped out the same day they are placed, as they understand the urgent needs of their clients and customers. They offer same-day delivery within the Greater Toronto Area if the order is placed before 11:00 AM EST. They provide priority shipping from coast to coast, ensuring their customers receive their personal protective equipment as soon as possible, regardless of where they are in the country. The company has also partnered with Uber Eats Canada, making its items readily available to local consumers. PPE Supply Canada is equipped with a team that handles the needs and requests of all B2B clients, ensuring extraordinary customer service, fast shipping times and happy customers. PPE Supply Canada is Registered with Health Canada. It holds its Health Canada Medical Device Establishment License (MDEL) which permits the company to manufacture, distribute and import medical devices in Canada.

Share article on social media or email:

ClinOne CEO Andrea Valente Joins Distinguished Panel to Discuss Clinical Research Technology at Row Associates Healthcare rpm 2022


ClinOne CEO Andrea Valente

“I’m excited to join this important event with leaders shaping the future of clinical research. Row Associates’ inspired agenda spans the healthcare continuum, including clinical trials. I look forward to discussing strategies and challenges and learning from colleagues.” -ClinOne CEO Andrea Valente

ClinOne, the leading provider of Adaptive Experiences for clinical trials, today announced that CEO Andrea Valente (LinkedIn) will join a distinguished panel to discuss clinical research technology at Healthcare rpm 2022 presented by Row Associates.

Healthcare rpm 2022 will be held on October 10-11 at the renowned Country Music Hall of Fame and Museum in downtown Nashville, Tennessee. It is anchored in important conversations, moderated by key industry figures, with C-suite leadership from vibrant segments of the healthcare landscape where significant change is actively taking shape. The privately-held event will gather senior executives and private equity leadership from across the healthcare spectrum.

The Evolving Paradigms in Clinical Research session will feature engaging and thought-provoking conversations with a visionary panel of experts:

–Paul Bleicher, MD, PhD (Moderator) – Executive Partner, Ardan Equity; Former Chief Executive Officer, Optum Labs; Founder and Former Chief Medical Officer, Humedica; Founder and Former Chief Executive Officer, Phase Forward

–Andrea Valente – Chief Executive Officer, ClinOne

–Colleen Hoke – Co-Founder and Chief Executive Officer, ObjectiveHealth

–Drew Bustos, Chief Strategy and Marketing Officer, Science 37

–Julie Schiffman, Chief Delivery Officer, Aetion

“All aspects of healthcare are changing rapidly, and I am excited to participate in this important event with proven leaders who are actively shaping the future of clinical research,” said Andrea Valente. “Row Associates has put together an inspired agenda that spans the healthcare continuum, including clinical trials, and I look forward to sharing strategies, discussing challenges, and learning from fellow panelists and attendees at Healthcare rpm 2022.”

To see more Adaptive Experiences on the ClinOne true single platform, visit http://www.clinone.com.

About ClinOne

ClinOne connects, informs, and empowers patients, caregivers, and sites in clinical trials with a true single platform for trial awareness, eConsent, medication adherence, Uber Health, eDiaries, and decentralized clinical trials (DCT). Used by more than 55 sponsors, CROs, and site networks in 60 countries, our solutions are proven to reduce risk and simplify complex processes for therapeutic areas and patient populations including Oncology, Rare Disease, Pediatrics, the Elderly, and CNS. Designed in collaboration with sites and with caregivers in mind, ClinOne features the industry’s fastest deployment, cost-efficient scale for trials of all sizes, and seamless API integrations to provide the results you need – and the experience your patients deserve. Ready to keep patients, sites, and study teams active and engaged throughout your clinical trial? Let’s get creative at http://www.clinone.com

Share article on social media or email:

Aktiv Pharma Group wins contract valued at up to $220 million to supply life-saving emergency autoinjectors to the Strategic National Stockpile


Aktiv Pharma Group (Aktiv) today announced a procurement contract award from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Under this contract (number 75A50122C00082), awarded under the 2004 Project BioShield Act, Aktiv will supply emergency autoinjectors containing pralidoxime chloride (2-PAM) to the CHEMPACK program, targeting proposed indications related to organophosphate poisoning including nerve agents. The total value of the contract, including options to continue supplying the product until 2029, is up to $220 million. “We are humbled by the opportunity to support the U.S. Government to enhance its readiness and preparedness to protect the U.S. civilian population and provide peace-of-mind to the emergency first responders if they have to use these products,” said the company founder and CEO, Amir Genosar.

The ARAI autoinjector has been developed by Aktiv with the support of the Department of Defense (DoD) and BARDA as a next generation autoinjector platform to address the shortfalls of previous autoinjectors, by improving usability, reliability, robustness, and drug stability. ARAI is a versatile platform that can deliver up to 5 ml dose volumes, perform simultaneous injections of multiple, separately stored drug formulations, and automatically reconstitute drugs formulated in dry form. Aktiv is currently expanding the ARAI platform to include a consumer market autoinjector for biopharmaceuticals that will feature the same reliability, robustness, and usability benefits in a smaller form factor and with added data connectivity.

Aktiv is leveraging its superior autoinjector technology to advance the strongest emergency treatment pipeline in the industry, which currently includes atropine, pralidoxime chloride (2-PAM), atropine/2-PAM dual-injection, scopolamine, and tranexamic acid (TXA). Aktiv is also collaborating with another pharmaceutical company to develop a reconstitution autoinjector for a long-acting formulation of naloxone.

About Aktiv

Aktiv is a vertically integrated specialty pharmaceutical company with combination product contract development and manufacturing organization (CDMO) capabilities, developing, manufacturing, and commercializing sterile injectable products in a portfolio of proprietary, value-added, glass-free prefilled delivery systems. Aktiv’s has unique combination product competencies, specifically targeting biopharmaceuticals. The company’s facilities in Colorado include device development, chemistry, manufacturing and controls (CMC), and manufacturing equipment labs, assembly rooms operated under current Good Manufacturing Practice (cGMP), and sterile fill-finish suites. Aktiv can be reached at https://aktivpharmagroup.com/contact.

Share article on social media or email:

Miami-Based Clinical Trial Company Tests First Drug For People Who Overuse Marijuana


News Image

Aelis Farma’s drug has the potential to make a significant, positive impact for millions of marijuana users seeking to end their dependence on cannabis.

Segal Trials, a privately held network of clinical research sites throughout South Florida, announced it will conduct a Phase 2B study to investigate a new drug, AEF0117-202, created by Aelis Farma to treat cannabis use disorder. No approved pharmacological treatments exist for people suffering from cannabis use disorder, so this randomized, double-blind, parallel group trial has the potential to pave the way toward a major advancement in the world of substance abuse treatment. For the first time, people who overuse marijuana may have access to a pill that can help them kick their habit.

AEF0117-202 is the first clinical candidate in a new pharmacological class of drugs, sCB1-SSi, for people who use cannabis at least five days per week. The orally administered drug will be given to a group of study participants while a second group will receive a placebo.

“Chronic marijuana use can drastically impact individuals’ social and professional lives in many ways, from poor work or school performance to mood disorders,” said Rishi Kakar, MD, chief scientific officer and medical director at Segal Trials. “This Phase 2B study gets us closer to the prospect of effectively treating people who want to end their reliance on cannabis but don’t have the tools to quit.”

Marijuana is the most commonly used drug in the United States, and, while drugs like cocaine and nicotine are far more addictive, up to 30% of regular cannabis users develop a dependence on the drug. What’s more, people who begin using cannabis before the age of 18 are four to seven times more likely to develop cannabis use disorder than adults.

People with a marijuana or cannabis dependence may feel withdrawal symptoms when not taking the drug, including irritability, mood and sleep difficulties, decreased appetite, cravings, restlessness, and even physical discomfort. Behavioral intervention, including cognitive-behavioral therapy, has shown to help patients treated for marijuana addiction. For some, though, therapy does not work, and few alternatives exist.

“The potency of cannabis products has increased significantly over the past twenty years,” which may have contributed to the rise of cannabis-related adverse effects,” said, Dr. Kakar. “With no approved drugs available to treat chronic cannabis use, Aelis Farma’s drug has the potential to make a significant, positive impact for millions of marijuana users seeking to end their dependence on cannabis.”

The Segal team will conduct the trial at its Center for Psychedelic and Cannabis Research, which was specifically built using pharmaceutical and regulatory feedback to create a structured inpatient environment that ensures both patient safety and patient comfort. Segal Trials also recently announced it was the first in the United States to conduct a large, randomized clinical trial to investigate MM-120 (LSD D-tartrate) to treat Generalized Anxiety Disorder (GAD).

For more information about Segal Trials, or to schedule an interview, please contact Meieli Sawyer at msawyer@weinbachgroup.com.

About Segal Trials

Segal Trials, founded in 1998, is a privately held network of research sites throughout South Florida conducting Phase I-IV research trials that have led to 54 FDA-approved medications and devices. The company’s trials focus on psychiatry, neurology, addiction, insomnia, infectious diseases, vaccine development, and women’s health; and it runs trials in outpatient, inpatient, PSG, and residential care facility settings.

Share article on social media or email:

SLK to Celebrate Chattanooga Grand Opening with Live Demos, Giveaways, Food and Drinks From Local Vendors


SLK’s mission is to offer Tennessee an aesthetic dermatology experience that balances science and luxury says Jennifer Stieber.

SLK will host a Grand Opening Celebration on Tuesday, October 18, from 4-7 p.m. at its Riverfront location, 804 Riverfront Parkway, featuring live demos, giveaways, service discounts, as well as food and drinks from local vendors. The event is open to anyone interested in dermatology, skincare and beauty, as well as the clinic’s neighbors in the Riverfront community.

The new SLK aesthetic dermatology clinic (pronounced “silk”) offers Botox, fillers, skin tightening, laser hair removal, skin resurfacing, fat removal, acne treatments and other medical-grade services in a luxury environment with an all-licensed nurse and nurse practitioner staff. Guests at the opening event will have the opportunity to talk with founder and chief nurse practitioner Jennifer Stieber, and the rest of the SLK medical team. There will also be live demos of the following procedures including:


  • Platelet-Rich Plasma, an infusion of a serum made with your own blood, a procedure that stimulates stem cell activity to enhance youthfulness of skin, accelerates scar healing, or even helps with hair restoration.
  • The Vivace Experience® RF Microneedling, the premier device for skin tightening, skin resurfacing, scar removal, and anti-aging on the face and body.
  • Colorescience, the premier skincare line for anti-aging and non-toxic sun protection.

“SLK’s mission is to offer Tennessee an aesthetic dermatology experience that balances science and luxury, ” says Jennifer Stieber. “We only offer procedures that are clinically-proven to produce results and the highest level of service by creating a customized treatment plan for each patient.”

Join SLK on October 18 to learn more about their approach to aesthetic dermatology, or visit the website slkclinic.com to book a consultation or service.

About SLK: Established in Nashville Tennessee in 2019, SLK, the ultimate destination for the best aesthetic medicine and beauty, was born of the belief that cosmetic dermatology should compliment nature. SLK was founded by Jennifer Stieber, MS, MPH, AGACNP-BC, a former research biochemist and director of clinical operations at one of the leading aesthetic dermatology practices in New York City. The aesthetic dermatology clinic mission is to provide patients with services rooted in wellness and graceful aging. Staffed by licensed nurses, SLK uses a rigorous, systematic selection process to vet new technologies, and periodically re-examine its curated services for efficacy and safety. Chattanooga is the second SLK location.

To learn more visit: slkclinic.com.

Share article on social media or email:

Pine Grove Behavioral Health & Addiction Services earns Three-Year CARF Accreditation


Pine Grove Behavioral Health & Addiction Services

Pine Grove Behavioral Health & Addiction Services

“This important achievement certainly took the whole Pine Grove team coming together.”

CARF International announced that Pine Grove Behavioral Health & Addiction Services has been accredited for a period of three years for its adult Intensive Outpatient Treatment: Substance Use Disorders (SUD) program, the Partial Hospitalization: Integrated: SUD / Mental Health treatment program for adults, and its Residential Treatment: Integrated: SUD / Mental Health treatment program for adults.

This is the first accreditation that the international accrediting body, CARF, has given to Pine Grove. This accreditation was the result of a concentrated team effort on Pine Grove’s behalf. Debbie Sanford, RN, MS, MBA, Pine Grove’s Administrator said, “I am very appreciative of every Pine Grove staff member, who contributed many hours towards this accreditation, checking charts, writing policies, and ensuring staff education and competencies. This important achievement certainly took the whole Pine Grove team coming together.”

This accreditation decision represents the highest level of accreditation that can be given to an organization and shows the organization’s substantial conformance to the CARF standards. An organization receiving a Three-Year Accreditation has put itself through a rigorous peer review process. It has demonstrated to a team of surveyors during an on-site visit its commitment to offering programs and services that are measurable, accountable, and of the highest quality.

Located in South Mississippi, Pine Grove Behavioral Health & Addiction Services is one of the nation’s most comprehensive treatment campuses. Pine Grove’s world renowned programs treat gender specific substance abuse including specialized tracks for co-occurring eating disorders and trauma. Additionally, Pine Grove offers an Intensive Outpatient substance abuse healing program for adults and a separate treatment track specifically for those who are age 55 plus. Other Pine Grove specialty programs include a dedicated professional’s treatment curriculum and a comprehensive evaluation center. Pine Grove also features a program for patients with sexual addiction. Inpatient Services including an Adult Psychiatric Unit, along with a Child and Adolescent Psychiatric Unit, and Outpatient Services are other components. Pine Grove is a division of Forrest Health, a partnership of healthcare organizations across South Mississippi, and the behavioral healthcare extension of Forrest General Hospital, a 547 bed, level II Regional Trauma Center. Established in 1984, Pine Grove has provided nationally and internationally recognized health care for 38 years. For more information, please visit http://www.pinegrovetreatment.com and call 1-888-574-HOPE (4673).

CARF is an independent, nonprofit accrediting body whose mission is to promote the quality, value, and optimal outcomes of services through a consultative accreditation process and continuous improvement services that center on enhancing the lives of the persons served. Founded in 1966 as the Commission on Accreditation of Rehabilitation Facilities, and now known as CARF International, the accrediting body establishes consumer-focused standards to help organizations measure and improve the quality of their programs and services. For more information about the accreditation process, please visit the CARF website at http://www.carf.org.

Share article on social media or email:

Impact Advisors Ranked #21 on Modern Healthcare’s Best Places to Work List


We will always make culture a focus so our associates can continue to provide high-quality outcomes for our clients.

Impact Advisors, a leading healthcare consultancy providing strategy, operations, revenue cycle, and technology services, was ranked #21 on Modern Healthcare’s Best Places to Work in Healthcare list. This is the 13th consecutive year the firm was named to the list in the supplier category.

“We are immensely honored to be ranked 21st on Modern Healthcare’s Best Places to Work list,” said Andy Smith, managing partner and co-founder of Impact Advisors. “Culture has been a top priority for our firm since the day we opened our doors 15 years ago and our commitment to our people has never wavered through our firm’s growth or changes in the industry. We will always make culture a focus so our associates can continue to provide high-quality outcomes for our clients.”

Modern Healthcare’s Best Places to Work in Healthcare list is compiled using information gathered from employers and employees of companies with at least 25 employees. Employees are surveyed to evaluate their employer in several areas, including leadership and planning, culture and communications, role satisfaction, working environment, relationships with supervisors, training, and development, pay and benefits, and overall satisfaction. This year’s program honors 150 organizations that empower employees to provide patients and customers with the best possible care, products, and services.

“We want to thank our associates for helping our firm achieve this amazing honor,” said Michael Nutter, vice president and happyologist at Impact Advisors. “This recognition speaks to their passion and dedication to a culture that supports our guiding principles and mission to create a positive impact in the healthcare industry. Attaining this recognition for 13 years in a row is a wonderful feat and we look forward to celebrating with our Impact family.”

Impact Advisors was honored at the 2022 Best Places to Work gala on Sept. 29 in Nashville.

In addition to Modern Healthcare’s recognition, Impact Advisors has earned several other workplace awards, including Consulting magazine’s Best Large Firms to Work For, Becker’s Healthcare’s 150 Great Places to Work in Healthcare, and Inc. magazine’s Best Workplaces.

About Impact Advisors

Impact Advisors is a nationally recognized healthcare management consulting and technology services firm that is solving some of the toughest challenges in the industry by delivering strategic advisory, technology implementation and operational improvement services. Our comprehensive suite of strategic planning, digital health, clinical optimization and revenue cycle services spans the lifecycle of our clients’ needs. Our experienced team has a powerful combination of clinical, revenue, operations, consulting and information technology experience. The firm has earned several prestigious industry and workplace awards including Best in KLAS® for 15 consecutive years, Healthcare Informatics HCI 100, Crain’s Chicago Business Fast Fifty, as well as “best place to work” awards from: Modern Healthcare, Consulting Magazine, Becker’s Hospital Review and Achievers. For more information about Impact Advisors, visit http://www.impact-advisors.com.

Share article on social media or email:

McArthur Medical Sales Inc. Receives ISO 13485:2016 & MDSAP Certification


McArthur Medical Achieves ISO 13486:2016 and MDSAP Certification

“McArthur Medical is excited to achieve this milestone, enabling us to provide Canadian manufactured innovations to clinicians, which greatly enhances therapy for the patients they serve. In addition, it provides the framework to continue to grow the MMSI-brand portfolio.”

McArthur Medical Sales Inc., a Canadian leader in medical devices for neonatal, anesthesia, and respiratory care has received both ISO 13485 medical manufacturing certification and Medical Device Single Audit Program certification (MDSAP).

McArthur Medical Sales Inc. (MMSI) celebrates its MDSAP certification for its unique respiratory products, ODAPT ™, EXHALO ™, and the international award winning Flusso adapters, Flusso By Pass ™ and Flusso TFI ™. The MDSAP certification means that products meet the requirements of current regulatory standards required for medical devices by Health Canada. Kyle McArthur, General Manager, said, “McArthur Medical is excited to achieve this milestone, enabling us to provide Canadian manufactured innovations to clinicians, which greatly enhances therapy for the patients they serve. In addition, it provides the framework to continue to grow the MMSI-brand portfolio.”

The management team at McArthur Medical made a decision to move ahead to implement a quality management system as the first step to preparing for ISO certification. “Certification to the standard requires an organization’s quality management system to pass a third-party Medical Device Single Audit Program, and we knew that becoming certified would be an important step to ensuring continued success in of our company,” said McArthur.

McArthur Medical Sales is a family-owned and operated distributor and manufacturer of medical equipment. Founded in 1984, McArthur Medical has built a reputation as an industry leader in medical device distribution boasting a team with over 225 years of clinical experience. In the last several years, it has developed a number or respiratory medical products available in several countries. “As we’ve continued to grow and advance in the industry, undergoing the process to become ISO/MDSAP certified just made sense,” added McArthur.

To learn more about McArthur Medical and its product offerings, visit http://www.mcarthurmedical.com

Share article on social media or email:

Medical Device and Diagnostic Reimbursements Expert Joins NDA Partners as Expert Consultant


News Image

Ms. Gendrolis’ expertise provides a valuable addition to the services that we provide to companies developing reimbursement strategy as part of early-stage development planning.

NDA Partners’ General Manager, Eric Fish, announced today that Catherine Gendrolis, a medical device and diagnostic reimbursement expert, has joined the firm as an Expert Consultant. She is experienced in coding and reimbursement analysis across government-sponsored and commercial health plans, sustainable finance planning, outcomes and impact analysis, payor landscape assessment, and payor contracting and negotiation strategy including value-based purchasing arrangements.

Ms. Gendrolis formerly served as Director at Precipio Health Strategies where she conducted due diligence for private equity firms focused on lower middle market investments in pharmaceutical, biotechnology, medical device, diagnostic, and life science companies. Currently, she serves as a strategic advisor to health plan and provider clients in the development, financing, contracting and implementation of innovative solutions and benefits that address the needs of Medicare and Medicaid beneficiaries. She served as Adjunct Faculty at the University of Baltimore where she taught Health Insurance and Prepaid Health Care and Introduction to Quality Performance and Improvement in Health Care, has authored reimbursement-focused works including The Hospice Guide to Billing and Reimbursement, and presented at numerous health care and life sciences conferences.

“Ms. Gendrolis’ expertise provides a valuable addition to the services that we provide to companies developing reimbursement strategy as part of early-stage development planning. We are pleased to welcome her to our team of Expert Consultants,” said Ms. Deb Koeneman, Manager of NDA Partners’ medical device practice.

Ms. Gendrolis earned her master’s degree in Health Systems Management from the University of Baltimore and a bachelor’s degree in Spanish from Tulane University.

About NDA Partners

NDA Partners, a ProPharma Group company, is a life sciences management consulting and contract development organization focused on providing product development and regulatory services to the pharmaceutical, biotechnology, and medical device industries worldwide. The highly experienced Expert Consultants in NDA Partners include three former FDA Center Directors; the former Chief Executive Officer and Chief Science Officer at the United States Pharmacopeial Convention (USP); an international team of more than 100 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, product development program design and management, expert consulting, functional teams, project-based solutions, and clinical trial design and management.

Contact

Eric Fish, General Manager

Office: 540-738-2550

FishEric@ndapartners.com

Share article on social media or email:

The Top 25 Healthcare Technology Leaders of Houston for 2022


The Healthcare Technology Report is pleased to announce The Top 25 Healthcare Technology Leaders of Houston for 2022. Houston is home to the Texas Medical Center, which is the world’s largest medical complex by several measures, including number of hospitals, number of physicians, square footage, and patient volume. In fact, nearly one in eight Houston workers are employed in the healthcare or social assistance fields. Houston is also home to some of the most innovative healthcare technology companies in the world, which with the guidance and expertise of their leaders are revolutionizing the healthcare industry and the level of care patients receive in fields as wide ranging as cardiac imaging, pharmaceuticals, nerve modulation, and sleep apnea.

Some of the distinguished honorees on this year’s list include Jeffrey Wade, President and CFO of Lexicon Pharmaceuticals, which has advanced new therapies across a wide spectrum of human disease, from diabetes to carcinoid syndrome. Meanwhile, SVP of R&D and CTO John Harper’ MiMedx is developing and distributing human placental tissue allografts for wound care with patent-protected processes. And SVP of Customer Experience Arin Barooah’s Acutus Medical designs, manufactures, and markets a range of tools for catheter-based ablation procedures, such as novel access sheaths and transseptal crossing tools, to treat various arrhythmias.

The awardees on this year’s list lead from a variety of positions, from CEOs and Presidents to COOs, CTOs, VPs, and Directors. What they have in common, however, is the level of knowledge they bring to their roles and their dedication to leading their organizations to develop the best products and services possible to improve the lives of patients. Please join us in celebrating The Top 25 Healthcare Technology Leaders of Houston for 2022.

Jimmy Youngblood (OsteoStrong), Jeffrey Wade (Lexicon Pharmaceuticals, Inc.), John Harper (MiMedx), Shakil Lakhani (InMode), Amy Castillo (Houston Forensic Science Center, Inc.), Michael Brown (Thomas Scientific), Brian Crum (Lexicon Pharmaceuticals, Inc.), Arin Barooah (Acutus Medical, Inc.), Ike Ogbaa (Chinook Therapeutics, Inc.), Chris Owens (Gynesonics), Joanna Williams (Lexitas Pharma Services, Inc.), Tim Daugherty (Millar, Inc.), Jens Hüttges (Cardiac Imaging, Inc.), Fabby Tudic (Houston MRI & Diagnostic Imaging), Namita Gandhi (Hummingbird Bioscience), Janet Stump (The Marena Group), Kimberly Wilkinson (Avation Medical), Ersin Bayram, PhD (Perimeter Medical Imaging AI), Diane Markesich (CSSi LifeSciences), Zac Potter (Treace Medical Concepts, Inc.), Johnny Goodman (CPAP.com), Praveen Kudithipudi (Deep Genomics), Cindy Ulmet-Frangullie (Shared Imaging, LLC), Corey Dixon (Omniscient Neurotechnology), Kelly Jenkins (Gene by Gene).

The full article can be read at https://thehealthcaretechnologyreport.com/

About The Healthcare Technology Report

The Healthcare Technology Report provides market research and insights, business news, investment activity updates, and important corporate developments related to the healthcare technology sector. Based in New York City, the firm is run by a seasoned team of editors, writers, and media professionals highly knowledgeable on healthcare technology and the various companies, executives, and investors that make up the sector.

Share article on social media or email: